CARB-X is funding Evotec to develop a new class of broad-spectrum antibiotics

CARB-X is funding Evotec to develop a new class of broad-spectrum antibiotics

  • 11/08/2020

Evotec is the first pharmaceutical R&D company based in Germany in the CARB-X portfolio

CARB-X announced today that it is awarding up to US$2.91 million to Evotec SE, a drug discovery and development company headquartered in Hamburg, Germany, to develop a new class of antibiotics to treat infections caused by deadly multidrug-resistant Gram-positive and Gram-negative bacteria. Evotec will be eligible for an additional $5.53 million in non-dilutive funding from CARB-X if project milestones are met, subject to available funds.

Read more here >>